Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.…
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals (NASDAQ: ELDN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 1.780 USD on 20 November 2026, down 13.6% over 52 weeks. Its 52-week range is 1.350 USD to 4.490 USD: the price is 60.4% below the high and 31.9% above the low.
Its market capitalisation is 150.34M USD.
Eledon Pharmaceuticals reports return on equity of -56.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 69.30M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.